Sage Therapeutics, Inc. (NASDAQ:SAGE) is reporting second quarter financial results on Monday 10th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, SAGE is expected to report 2Q20 loss of $ 2.66 per share from revenue of $ 0.89 million.
For the full year, analysts anticipate top line of $ 9.58 million, while looking forward to loss of $ 10.01 per share bottom line.
Previous Quarter Performance
Sage Therapeutics, Inc. unveiled loss for the first quarter of $ 2.44 per share, from the revenue of $ 2.29 million. According to street consensus, SAGE was expected to report 1Q20 loss of $ 3.14 per share from revenue of $ 2.80 million. The bottom line results beat street analysts by $ 0.7 or 22.29 percent, at the same time, top line results fell short of analysts by $ 0.51 million or 18.21 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Sage Therapeutics, Inc.
Stock Performance
According to the previous trading day, closing price of SAGE was $ 50.70, representing a 102.72 % increase from the 52 week low of $ 25.01 and a 70.82 % decrease over the 52 week high of $ 173.76.
The company has a market capital of $ 2.63 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”SAGE” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Sage Therapeutics, Inc. will be hosting a conference call at 8:30 AM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.sagerx.com
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD). The companys product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and sleep disorders; and SAGE-324, a novel neuroactive steroid that has completed Phase I clinical trials to treat various neurological conditions, including essential tremor and epileptiform disorders.
